Literature DB >> 30355033

Effect of Intracoronary Metformin on Myocardial Infarct Size in Swine.

George Techiryan1, Brian R Weil1, Beth A Palka1, John M Canty1.   

Abstract

RATIONALE: Metformin has been demonstrated to decrease infarct size (IS) and prevent postinfarction left ventricular (LV) remodeling in rodents when given intravenously at the time of reperfusion. It remains unclear whether similar cardioprotection can be achieved in a large animal model.
OBJECTIVE: The objective of this study was to determine whether intravascular infusion of metformin at the time of reperfusion reduces myocardial IS in a porcine model of acute myocardial infarction. METHODS AND
RESULTS: In a blinded and randomized preclinical study, closed-chest swine (n=20) were subjected to a 60-minute left anterior descending coronary artery occlusion to produce myocardial infarction. Contrast-enhanced computed tomography was performed during left anterior descending coronary artery occlusion to assess the ischemic area-at-risk. Animals were randomized to receive either metformin or vehicle as an initial intravenous bolus (5 mg/kg) 8 minutes before reperfusion, followed by a 15-minute left coronary artery infusion (1 mg/kg per minute) commencing with the onset of reperfusion. Echocardiography and computed tomographic imaging of LV function were performed 1 week later, at which time the heart was removed for postmortem pathological analysis of area-at-risk and IS (triphenyltetrazolium chloride). Baseline variables including hemodynamics and LV function were similar between groups. Peak circulating metformin concentrations of 374±35 µmol/L were achieved 15 minutes after reperfusion. There was no difference between the area-at-risk as a percent of LV mass by computed tomography (vehicle: 20.7%±1.1% versus metformin: 19.7%±1.3%; P=0.59) or postmortem pathology (22.4%±1.2% versus 20.2%±1.2%; P=0.21). IS relative to area-at-risk averaged 44.5%±5.0% in vehicle-treated versus 38.2%±6.8% in metformin-treated animals ( P=0.46). There was no difference in global function 7 days after myocardial infarction as assessed by echocardiography or computed tomographic ejection fraction (56.2%±2.6% versus 56.3%±2.4%; P=0.98).
CONCLUSIONS: In contrast to rodent hearts, postconditioning with high-dose metformin administered immediately before reperfusion does not reduce IS or improve LV function 7 days after myocardial infarction in swine. These results reinforce the importance of rigorously testing therapies in large animal models to facilitate clinical translation of novel cardioprotective therapies.

Entities:  

Keywords:  infarction; metformin; models, animal; myocardial infarction; ventricular remodeling

Mesh:

Substances:

Year:  2018        PMID: 30355033      PMCID: PMC6207210          DOI: 10.1161/CIRCRESAHA.118.313341

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  22 in total

1.  Impact of electrical defibrillation on infarct size and no-reflow in pigs subjected to myocardial ischemia-reperfusion without and with ischemic conditioning.

Authors:  Andreas Skyschally; Georgios Amanakis; Markus Neuhäuser; Petra Kleinbongard; Gerd Heusch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-08-04       Impact factor: 4.733

2.  Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.

Authors:  Chris P H Lexis; Iwan C C van der Horst; Erik Lipsic; Wouter G Wieringa; Rudolf A de Boer; Ad F M van den Heuvel; Hindrik W van der Werf; Remco A J Schurer; Gabija Pundziute; Eng S Tan; Wybe Nieuwland; Hendrik M Willemsen; Bernard Dorhout; Barbara H W Molmans; Anouk N A van der Horst-Schrivers; Bruce H R Wolffenbuttel; Gert J ter Horst; Albert C van Rossum; Jan G P Tijssen; Hans L Hillege; Bart J G L de Smet; Pim van der Harst; Dirk J van Veldhuisen
Journal:  JAMA       Date:  2014-04-16       Impact factor: 56.272

Review 3.  Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning.

Authors:  Gerd Heusch
Journal:  Circ Res       Date:  2015-02-13       Impact factor: 17.367

4.  The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs.

Authors:  Steven P Jones; Xian-Liang Tang; Yiru Guo; Charles Steenbergen; David J Lefer; Rakesh C Kukreja; Maiying Kong; Qianhong Li; Shashi Bhushan; Xiaoping Zhu; Junjie Du; Yibing Nong; Heather L Stowers; Kazuhisa Kondo; Gregory N Hunt; Traci T Goodchild; Adam Orr; Carlos C Chang; Ramzi Ockaili; Fadi N Salloum; Roberto Bolli
Journal:  Circ Res       Date:  2014-12-11       Impact factor: 17.367

5.  Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.

Authors:  Marta Paiva; Niels P Riksen; Sean M Davidson; Derek J Hausenloy; Pedro Monteiro; Lino Gonçalves; Luís Providência; Gerard A Rongen; Paul Smits; Mihaela M Mocanu; Derek M Yellon
Journal:  J Cardiovasc Pharmacol       Date:  2009-05       Impact factor: 3.105

6.  Metformin mitigates apoptosis in ischemic myocardium.

Authors:  Nassrene Y Elmadhun; Ashraf A Sabe; Antonio D Lassaletta; Louis M Chu; Frank W Sellke
Journal:  J Surg Res       Date:  2014-05-17       Impact factor: 2.192

7.  Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure.

Authors:  Susheel Gundewar; John W Calvert; Saurabh Jha; Iris Toedt-Pingel; Sang Yong Ji; Denise Nunez; Arun Ramachandran; Mauricio Anaya-Cisneros; Rong Tian; David J Lefer
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

Review 8.  Is Cardioprotection Dead?

Authors:  David J Lefer; Eduardo Marbán
Journal:  Circulation       Date:  2017-07-04       Impact factor: 29.690

9.  Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.

Authors:  Hannah J Whittington; Andrew R Hall; Catarina P McLaughlin; Derek J Hausenloy; Derek M Yellon; Mihaela M Mocanu
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

10.  Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs.

Authors:  Alessandro Protti; Francesco Fortunato; Massimo Monti; Sarah Vecchio; Stefano Gatti; Giacomo P Comi; Rachele De Giuseppe; Luciano Gattinoni
Journal:  Crit Care       Date:  2012-05-08       Impact factor: 9.097

View more
  14 in total

1.  Nonocclusive multivessel intracoronary infusion of allogeneic cardiosphere-derived cells early after reperfusion prevents remote zone myocyte loss and improves global left ventricular function in swine with myocardial infarction.

Authors:  Gen Suzuki; Brian R Weil; Rebeccah F Young; James A Fallavollita; John M Canty
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

2.  Mitochondrial Complex I Inhibition by Metformin Limits Reperfusion Injury.

Authors:  Ahmed A Mohsin; Qun Chen; Nanhu Quan; Thomas Rousselle; Michael W Maceyka; Arun Samidurai; Jeremy Thompson; Ying Hu; Ji Li; Edward J Lesnefsky
Journal:  J Pharmacol Exp Ther       Date:  2019-03-07       Impact factor: 4.030

3.  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

Authors:  Maaike Te Lintel Hekkert; Gary Newton; Dirk J Duncker; Michael D Schneider; Kathryn Chapman; Rehan Aqil; Robert Downham; Robert Yan; Daphne Merkus; Gavin Whitlock; Charlotte A L Lane; Darren Cawkill; Trevor Perrior
Journal:  Basic Res Cardiol       Date:  2021-05-20       Impact factor: 17.165

4.  Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study.

Authors:  Daniel I Bromage; Tom R Godec; Mar Pujades-Rodriguez; Arturo Gonzalez-Izquierdo; S Denaxas; Harry Hemingway; Derek M Yellon
Journal:  Cardiovasc Diabetol       Date:  2019-12-09       Impact factor: 8.949

5.  Metformin protects against cardiac and renal damage in diabetic cardiac arrest patients.

Authors:  Cody A Rutledge; Brett A Kaufman; Cameron Dezfulian; Jonathan Elmer
Journal:  Resuscitation       Date:  2022-03-21       Impact factor: 6.251

6.  Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure.

Authors:  Thomas R Godec; Daniel I Bromage; Mar Pujades-Rodriguez; Antonio Cannatà; Arturo Gonzalez-Izquierdo; Spiros Denaxas; Harry Hemingway; Ajay M Shah; Derek M Yellon; Theresa A McDonagh
Journal:  ESC Heart Fail       Date:  2022-03-23

Review 7.  New advances in perioperative cardioprotection.

Authors:  Mona Momeni; Stefan De Hert
Journal:  F1000Res       Date:  2019-04-24

Review 8.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15

9.  Neutrophils aid cellular therapeutics by enhancing glycoengineered stem cell recruitment and retention at sites of inflammation.

Authors:  Arezoo Momeni; Lisa Eagler; Chi Y Lo; Brian R Weil; John M Canty; Jennifer K Lang; Sriram Neelamegham
Journal:  Biomaterials       Date:  2021-07-27       Impact factor: 15.304

10.  Metformin mediates cardioprotection against aging-induced ischemic necroptosis.

Authors:  Chen Li; Nan Mu; Chunhu Gu; Manling Liu; Zheng Yang; Yue Yin; Mai Chen; Yishi Wang; Yuehu Han; Lu Yu; Heng Ma
Journal:  Aging Cell       Date:  2020-01-14       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.